BAM
NVCR icon

Blueshift Asset Management’s NovoCure NVCR Stock Holding History

Blueshift Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,184
Closed -$706K – 1210
2021
Q2 		$706K Sell
3,184
-64
-2% -$12.4K 0.04% 451
2021
Q1 		$429K Buy
+3,248
New +$514K 0.04% 523
2019
Q2 		– Sell
-5,598
Closed -$270K – 893
2019
Q1 		$270K Buy
+5,598
New +$269K 0.04% 564

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Blueshift Asset Management's NVCR Position: Q3 2021 in Review

Blueshift Asset Management sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 3,184 shares — an estimated $706K sold.

Blueshift Asset Management first reported a position in NVCR in Q1 2019 and held it in 3 quarters. The position peaked at $706K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Blueshift Asset Management reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 3,184 NovoCure shares in Q3 2021, an estimated $706K.
  • Blueshift Asset Management first reported a position in NovoCure in Q1 2019 and held it in 3 quarters.
  • Blueshift Asset Management's NovoCure position peaked at $706K in Q2 2021.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Blueshift Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.